Eton Pharmaceuticals vs Xeris Biopharma
ETON and XERS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ETON and XERS compare
Xeris Biopharma is the larger company, worth 1.7 times as much as Eton Pharmaceuticals ($3.0B against $1.8B).
Eton Pharmaceuticals grew revenue faster over the last twelve months (101% versus 38.4% for Xeris Biopharma).
Eton Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 35.3% compared with −1.8% at Xeris Biopharma.
Eton Pharmaceuticals scores higher on the StockData Score (12 against 11 for Xeris Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ETON | XERS |
|---|---|---|
| Size and price | ||
| Market cap | $1.8B | $3.0B |
| Share price | $63.93 | $16.66 |
| Change, 1 year | 266% | 119% |
| Change, 5 years | 1302% | 634% |
| Beta (5Y) | 0.88 | 1.15 |
| Employees | 44 | 435 |
| StockData Score | ||
| Total score | 12 (better) | 11 |
| Valuation score | 0 | 0 |
| Growth score | 4 | 4 |
| Performance score | 4 | 4 |
| Health score | 4 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 42.1× | – |
| P/S | 13.0× | 8.2× (better) |
| P/B | 21.0× (better) | 62.3× |
| EV/EBITDA | 39.3× (better) | 64.4× |
| P/FCF | 47.8× | – |
| FCF yield | 2.1% | – |
| Fair value | $33.76 | $3.65 |
| Margin of safety | −89.4% (better) | −357% |
| Growth | ||
| Revenue growth (TTM) | 101% (better) | 38.4% |
| Revenue growth, 5Y average | 360% (better) | 70.2% |
| Profitability | ||
| Gross margin | 69.2% | 87.4% (better) |
| Operating margin | 28.8% (better) | 12.7% |
| Net margin | 35.3% (better) | −1.8% |
| FCF margin | 27.1% | – |
| Return on equity | 90.6% (better) | −27.1% |
| Return on invested capital | 115% (better) | 31.5% |
| Financial health | ||
| Debt / equity | 0.27 (better) | 3.89 |
| Net debt / EBITDA | −0.71 | 1.22 (better) |
| Interest coverage | – | 1.7× |
| Current ratio | 1.79 | 2.15 (better) |
| Altman Z-score | 17.09 (better) | 4.26 |
| Piotroski F-score | 4 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 74.0% | 59.4% |
| Held by insiders | 5.6% | 5.2% |
| Insider net buying, 12 months | −$35.0M | −$5.8M (better) |
| Short interest, % of float | 7.4% | 5.2% |
Go deeper
- ETON stock overview
- ETON income statement
- ETON valuation and score
- XERS stock overview
- XERS income statement
- XERS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.